Calistoga Pharmaceuticals` CAL-101, an Oral Delta Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Clinical Benefit in Patients with Relapsed or Refractory Indolent Non-Hodgkin`s Lymphoma, Mantle Cell Lymphoma and Chroni